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Abstract
Background
Nonalcoholic fatty liver disease (NAFLD) is known to be strongly associated with obesity,
visceral fat, metabolic syndrome (MS), lifestyle, and lifestyle-related diseases in both males
and females. However, the prevalence of NAFLD, MS, and clinical backgrounds is different
between males and females.
Objective
We conducted a cross-sectional study to examine the differing influence of lifestyle-related
factors and visceral fat on fatty liver (FL) with elevation of liver enzymes between males and
females with MS.
Methods
We enrolled 42,134 persons who underwent a regular health check-up, and after excluding
subjects who fulfilled excluding criteria, the remaining subjects were 2,110 persons with MS.
We examined the differing influence of lifestyle-related factors and visceral fat on FL with
elevation of alanine aminotransferase (ALT) (ALT elevation was defined as ALT level of
31 IU/l in the present study).
Results
The odds rations for FL with ALT elevation were as follows: WC, 1.83 (95% confidence inter-
val (CI) 1.36–2.46); dyslipidemia, 1.89 (95% CI 1.34–2.68); hemoglobin A1c, 1.36 (95% CI
1.00–1.85); visceral fat type MS (V-type MS), 5.78 (95% CI 4.29–7.80); and light drinker,
PLOS ONE | https://doi.org/10.1371/journal.pone.0177925 June 2, 2017 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Sogabe M, Okahisa T, Nakasono M,
Fukuno H, Miyamoto Y, Okada Y, et al. (2017) The
differing influence of several factors on the
development of fatty liver with elevation of liver
enzymes between genders with metabolic
syndrome: A cross-sectional study. PLoS ONE 12
(6): e0177925. https://doi.org/10.1371/journal.
pone.0177925
Editor: Herve´ Guillou, INRA, FRANCE
Received: January 13, 2017
Accepted: May 5, 2017
Published: June 2, 2017
Copyright: © 2017 Sogabe et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
0.56 (95% CI 0.41–0.78) in males with MS and BMI, 2.18 (95% CI 1.43–3.33); WC, 1.85
(95% CI 1.27–2.70); diastolic blood pressure, 1.69 (95% CI 1.16–2.45); triglyceride, 2.22
(95% CI 1.56–3.17); impaired glucose tolerance, 1.66 (95% CI 1.11–2.47); and V-type MS,
3.83 (95% CI 2.57–5.70) in females with MS. The prevalence of FL with ALT elevation and
ALT was significantly higher in V-type MS than in the subcutaneous fat type MS in both
males and females with MS (P < 0.001).
Conclusion
Although V-type MS and WC is a common significant predictor of an increased prevalence
of FL with ALT elevation in both males and females with MS, gender, lifestyle-related fac-
tors, and MS type in individuals with MS should be considered for the development of FL
with ALT elevation.
Introduction
Metabolic syndrome (MS) is commonly defined as the presence of an increased waist circum-
ference (WC) and more than two of the following components: (i) high blood pressure and/or
medication for hypertension; (ii) hypertriglyceridemia, low levels of high-density lipoprotein
(HDL) cholesterol and/or medication for dyslipidemia; and (iii) hyperglycemia and/or medi-
cation for diabetes [1, 2]. In other words, MS is recognized as visceral fat with lifestyle-related
diseases. There has been a recent increase in the rate of individuals with MS in both developed
and developing countries due to economic growth and changes in lifestyle such as insufficient
physical exercise and excess food consumption [3]. It is now becoming accepted that MS is an
important issue concerning public health and medical expenses. MS has been highlighted as a
risk factor for ischemic heart disease and arteriosclerotic diseases, and has recently been
shown to be strongly associated with non-alcoholic fatty liver disease (NAFLD). Although MS
is associated with NAFLD in both sexes, the prevalence of MS and NAFLD is known to differ
between genders. In addition, several factors associated with MS, such as the distribution of
adipose tissue, lifestyle, and the prevalence of lifestyle-related diseases, also differ between gen-
ders. In this study, we elucidated the differing influence of lifestyle, lifestyle-related diseases,
and visceral fat on fatty liver (FL) with elevation of liver enzymes between genders with MS.
Methods
Subjects and study design
Forty two thousands one hundred thirty four Japanese adult subjects who underwent a regular
health check-up at our hospital between April 2008 and March 2013 were initially included in
this study. The exclusion criteria were as follows: (1) subjects who were positive for hepatitis B
surface antigen (HBsAg) and/or hepatitis C antibody (HCVAb); (2) subjects who did not fulfill
the diagnostic criteria for MS; (3) subjects who did not undergo an ultrasound; (4) male sub-
jects with an alcohol consumption of 20 g/day or more; (5) female subjects with an alcohol
consumption of 10 g/day or more; (6) subjects who had a history of liver surgery; and (7) sub-
jects who take and/or took medicine for liver disease. The regular health check-up included
taking a record of the previous medical history, present medical condition, conducting physi-
cal examination, and routine biochemical variables. Body weight and height of the subjects
were determined, and body mass index (BMI) was calculated. WC was measured at the
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umbilical level. The measurements of blood pressure was performed more than twice, while
the subjects were seated before collecting of blood samples. Venous blood samples were taken
from all subjects in the morning, after the subjects had fasted for more than 12 h overnight.
The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl
transpeptidase (GGT), total cholesterol (T-CHO), triglyceride (TG), HDL cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid (UA), fasting plasma glucose
(FPG), and hemoglobin A1c (HbA1c) were determined by common enzymatic methods using
an auto analyzer (TBA-80FR; Toshiba Medical System, Tokyo, Japan). All subjects were
informed that the clinical data obtained by the medical check-up may be retrospectively ana-
lyzed, and written informed consent was obtained. The present study was a retrospective
cross-sectional study clarifying the different influence of several factors on FL with ALT eleva-
tion between genders with MS. The study design was approved by the Ethics Committees of
Kagawa Prefectural Cancer Detection Center, and the study was performed in accordance
with the Declaration of Helsinki.
Questionnaire for lifestyle factors
Lifestyle-related information, including alcohol consumption, smoking status, and medical
history, were surveyed using a common standardized self-response questionnaire. Subjects
were divided into two categories based upon the smoking information: never smokers, who
had never smoked (Brinkman index (BI) [4] is zero); and smokers, who had a past history of
smoking (BI is more than one). The amount of alcohol consumed per drinking day was deter-
mined in grams using representative percent alcohol by volume for each type of alcohol. Based
upon the drinking information, subjects were divided into two categories: non-drinkers, males
drinking 12 drinks or less per year of less than 20 g/drinking day, or females drinking 12
drinks or less per year of less than 10 g/drinking day; and light drinkers, males drinking more
than zero but less than 20 g/drinking day, or females drinking more than zero but less than 10
g/drinking day.
Diagnosis of MS
The diagnostic criteria for MS adopted by International Diabetes Federation (IDF) was used in
this study [2]. Component factors of MS criteria are WC must exceed 85 cm for males or 80
cm for females, and the presence of two or more of the following: (1) dyslipidemia:
HDL-C < 40 mg/dl for males, HDL-C < 50 mg/dl for females, and/or TG150 mg/dl, or
medication for dyslipidemia; (2) impaired glucose tolerance (IGT): FPG100 mg/dl or medi-
cation for diabetes; (3) hypertension: blood pressure130/85 mmHg or medication for
hypertension.
Assessment of ultrasonography
Abdominal ultrasonography was performed with the subjects in a morning fasting state. An
Xario SSA-660A instrument with a 3.5 MHz convex-array probe (Toshiba Medical System,
Tokyo, Japan) was used for ultrasonography. The criteria of FL diagnosis by ultrasonography
were as follows: the FL must have liver-kidney echo contrast and liver brightness, as well as
having liver vessel blurring and/or deep attenuation [5, 6]. Although liver biopsy is the gold
standard for the diagnosis of NAFLD/nonalcoholic steatohepatitis (NASH), it is invasive and
not realistic to perform in a medical check-up. Thus, we investigated FL with ALT elevation
(ALT elevation was defined as ALT level of31 IU/l) in the present study. In addition, assess-
ment of visceral fat was performed using the abdominal wall fat index (AFI) that was defined
by the ratio of the maximal preperitoneal thickness and the subcutaneous fat thicknesses at the
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same time point, and had a significant correlation with the ratio of visceral and subcutaneous
fat areas by computed tomography (CT) [7]. The subcutaneous fat thickness was measured as
the distance from the skin to the linea alba and the preperitoneal fat thickness was measured as
the distance from the linea alba to the anterior surface of the liver. We defined AFI of at least 1
and AFI of less than 1 were regarded as V-type MS (in other words, dominant visceral type
MS) and S-type MS (in other words, dominant subcutaneous type MS), respectively.
Statistical analysis
Baseline data are expressed as the means ± standard deviation (SD). A P value of less than 0.05
was considered to be significant. Comparison of the proportion and the categorical variables
between two groups was performed using the χ2-test. One-way analysis of variance was used
to analyze the differences in baseline characteristics, such as age, physical examination, and
serum biochemistry, between two groups. Factors with a significant influence on the preva-
lence of FL with ALT elevation were determined by univariate analysis. Age, BMI, WC, and
factors that had a P value of less than 0.05 by univariate analysis were then subjected to a multi-
variate logistic regression analysis. The odds ratio (OR) and 95% confidence interval (CI) were
analyzed for each variable. All statistical analyses were performed using Med Calc Software
(Broekstraat, Mariakerke, Belgium).
Results
Enrollment of subject
The flowchart of the enrollment of subjects in the present study is shown in Fig 1. Forty two
thousands one hundred thirty four subjects underwent a regular health check-up between
April 2008 and March 2013 at our hospital. The enrolled subjects were selected by the inclu-
sion and exclusion criteria described in the method section (subjects and study design). Of the
initial 42,134 subjects, 5,526 (13.1%) subjects fulfilled the diagnostic criteria for MS. Of the
5,526 subjects, 2,651 subjects underwent all of the necessary tests for inclusion in the present
study including physical examinations, blood-test screening, abdominal ultrasonography, and
a self-response questionnaire. Of the 2,651 subjects, 541 fulfilled the exclusion criteria and
were excluded, and the remaining 2,110 subjects were enrolled in the present study.
Baseline characteristics of the subjects with MS
Baseline characteristics of the 2,110 enrolled subjects with MS are shown in Table 1. The pro-
portion of males and females was 50.4% (1,063 males), and 49.6% (1,047 females), respectively.
Mean age, mean BMI, and mean WC was 55.1 ± 9.2 years, 27.3 ± 3.6 kg/m2, and 93.3 ± 7.8 cm,
respectively in all subjects. The prevalence of hypertension, dyslipidemia, and IGT was 78.0%,
83.6%, and 78.7%, respectively. The proportion of subjects reported to have alcohol consump-
tion and a past history of smoking was 40.4% and 59.6%, respectively.
Comparison of clinical characteristics between males with MS and
females with MS
As shown in Table 2, BMI and WC were significantly higher in males with MS than in females
with MS (p<0.05). The prevalence of hypertension, dyslipidemia, and IGT was 74.6%, 74.1%,
and 83.1% in males with MS and 81.4%, 93.3%, and 74.2% in females with MS, respectively.
The prevalence of dyslipidemia was significantly higher in females with MS than in males with
MS (pa<0.001). The prevalence of FL, ALT, AST, and GGT were significantly higher in males
with MS than in females with MS (pa<0.001). The proportion of V-type MS in males with MS
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and females with MS was 61.8% and 14.7%, respectively, and the prevalence of V-type MS was
significantly higher in males with MS than in females with MS (pa<0.001). The proportion of
alcohol consumption in males with MS and females with MS was 73.8% and 23.9%, respec-
tively. The proportion of past history of smoking in males with MS and females with MS was
72.5% and 7.8%, respectively. The prevalence of subjects who have alcohol consumption or
past history of smoking was significantly higher in males with MS than in females with MS (p
<0.001).
Comparison of clinical characteristics in each MS type and each gender
As shown in Table 3, BMI and WC were significantly higher in V-type MS than S-type MS in
both males and females with MS. (P<0.001). There was no significant difference in SBP, DBP,
HDL, LDL, UA, FPG, and HbA1c between V-type MS and S-type MS in males with MS; how-
ever, TG, UA, FPG, and HbA1c in V-type MS was significantly higher in S-type MS in females
with MS. The prevalence of FL with ALT elevation, ALT, AST, and GGT was significantly
higher in V-type MS than in S-type MS in both males and females with MS. BMI and WC
were significantly higher in males than females in both MS type (p<0.001). DBP, TG, and
UA were significantly higher in males than females in both MS type (pa<0.05). HDL was sig-
nificantly higher in females than males in both MS type (pa<0.001). The prevalence of FL
with ALT elevation and ALT was significantly higher in males than females in V-type MS
(pa<0.01). The prevalence of alcohol consumption and past history of smoking was signifi-
cantly higher in males than in females in both MS type (p<0.001).
Independent predictors of FL with ALT elevation in males and females
with MS
Table 4 shows the univariate and multivariate analyses for independent predictors of FL with
ALT elevation in males and females with MS. Of the 20 items related to the clinical back-
ground of the subjects who had FL with ALT elevation or the subjects who did not have FL
Fig 1. Flow chart of subjects selection. MS, metabolic syndrome.
https://doi.org/10.1371/journal.pone.0177925.g001
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with ALT elevation, 15 and 14 items were identified as significant factors by univariate analysis
in males and females with MS, respectively. In males with MS, multiple logistic regression
analysis was performed with 9 items, with age, BMI, WC, hypertension, dyslipidemia, UA,
HbA1c, MS type, and status of drinking as covariates. Age, WC, dyslipidemia, HbA1c, and V-
type MS were significant and independent predictors of an increased prevalence of FL with
ALT elevation. Light drinker was a significant and independent predictor of a decreased preva-
lence of FL with ALT elevation. The OR (95% CI, p value) for FL with ALT elevation were as
follows: age, 2.874 (2.110–3.915, p<0.001); WC, 1.831 (1.360–2.464, p<0.005); dyslipidemia,
1.893 (1.339–2.676, p<0.005); HbA1c, 1.360 (1.003–1.845, p<0.05); V-type MS, 5.783 (4.288–
7.799, p<0.001); and light drinker, 0.563 (0.407–0.778, p<0.005). On the other hands, in
females with MS, multiple logistic regression analysis was performed with 10 items, with age,
BMI, WC, SBP, DBP, TG, HDL-C, UA, IGT, and MS type as covariates. BMI, WC, DBP, TG,
UA, IGT, and V-type MS were significant and independent predictors of an increased preva-
lence of FL with ALT elevation. The OR (95% CI, p value) for FL with ALT elevation were as
follows: BMI, 2.179 (1.425–3.332, p<0.001); WC, 1.850 (1.267–2.702, p<0.005); DBP, 1.687
Table 1. Subject characteristics.
Number 2110
Gender (male/female) (% male) 1063/1047 (50.4%)
Age (years) 55.1 ± 9.2 (21–85)
BMI (kg/m2) 27.3 ± 3.6 (18.5–50.8)
WC (cm) 93.3 ± 7.8 (80–141)
SBP (mmHg) 130.3 ± 14.7 (81–198)
DBP (mmHg) 78.9 ± 9.9 (45–127)
Hypertension (+/-) (% positive) 1645/465 (78.0%)
T-CHO (mg/dl) 208.2 ± 34.8 (93–380)
TG (mg/dl) 150.1 ± 91.6 (29–1353)
HDL (mg/dl) 54.3 ± 13.4 (26–127)
LDL (mg/dl) 134.5 ± 31.1 (48–286)
Dyslipidemia (+/-) (% positive) 1765/345 (83.6%)
UA (mg/dl) 5.7 ± 1.4 (1–10.9)
FPG (mg/dl) 111.1 ± 21.2 (65–272)
HbA1c (%) 6.1 ± 0.8 (4.3–12)
IGT (+/-) (% positive) 1660/450 (78.7%)
ALT (IU/l) 34.3 ± 24.6 (6–228)
AST (IU/l) 26.1 ± 12.9 (9–153)
GGT (IU/l) 51.0 ± 54.4 (7–663)
FIB-4 index 1.16 ± 0.66 (0.24–9.56)
Fatty liver (+/-) (% positive) 1401/709 (66.4%)
V-type MS / S-type MS (% V-type MS) 811/1299 (38.4%)
Alcohol consumption (+/-) (% positive) 1034/1076 (40.4%)
Past history of smoking (+/-) (% positive) 853/1257 (59.6%)
Data represent the mean ± standard deviation (SD).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic
blood pressure; FPG, fasting plasma glucose; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin
A1c; HDL, high-density lipoprotein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; MS,
metabolic syndrome; SBP: systolic blood pressure; S-type, subcutaneous type; T-CHO, total cholesterol;
TG, triglyceride; UA, uric acid; V-type, visceral type; WC, waist circumference.
https://doi.org/10.1371/journal.pone.0177925.t001
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(1.163–2.449, p<0.01); TG, 2.221 (1.558–3.166, p<0.001); UA, 2.911 (1.419–5.969, p<0.01);
IGT, 1.658 (1.112–2.471, p<0.05); and V-type MS, 3.828 (2.571–5.700, p<0.001).
The influence of the treatment for lifestyle-related diseases and lifestyle
on the prevalence of FL with ALT elevation in males and females with
MS
As shown in Table 5, although there was no significant difference in the prevalence of those
receiving treatment for hypertension between genders with MS, the prevalence of FL with
ALT elevation were significantly higher in males with MS than in females with MS in both
those with and without treatment for hypertension. The prevalence of those receiving treat-
ment for dyslipidemia was significantly higher in females with MS than in males with MS.
Additionally, the prevalence of FL with ALT elevation were significantly higher in males
with MS than in females with MS in both those with and without treatment for dyslipidemia.
Although the prevalence of those receiving treatment for IGT was significantly higher in males
Table 2. Comparison of clinical characteristics between males with MS and females with MS.
Males with MS Females with MS P-value
(n = 1063) (n = 1047) (Pa-value)
Age (years) 53.3 ± 9.7 (21–83) 56.8 ± 8.3 (29–85) <0.05
BMI (kg/m2) 28.2 ± 3.4 (21.6–49.3) 26.3 ± 3.5 (18.5–50.8) <0.05
WC (cm) 96.6 ± 7.1 (90–141) 90.0 ± 7.1 (80–117.5) <0.05
SBP (mmHg) 129.6 ± 15.0 (81–198) 131.0 ± 14.2 (83–192) (NS)
DBP (mmHg) 80.0 ± 10.2 (46–127) 77.8 ± 9.5 (45–114) (<0.001)
Hypertension, n (%) 793 (74.6%) 852 (81.4%) (NS)
T-CHO (mg/dl) 204.9 ± 36.1 (93–380) 211.6 ± 33.2 (96–329) (<0.05)
TG (mg/dl) 176.8 ± 106.1 (36–1353) 123.0 ± 63.4 (29–689) (<0.001)
HDL (mg/dl) 49.2 ± 10.9 (26–102) 59.6 ± 13.8 (33–127) (<0.001)
LDL (mg/dl) 133.5 ± 32.2 (48–286) 135.5 ± 29.9 (48–243) (NS)
Dyslipidemia, n (%) 788 (74.1%) 977 (93.3%) (<0.001)
UA (mg/dl) 6.4 ± 1.4 (1–10.9) 4.9 ± 1.1 (1.4–8.9) (<0.001)
FPG (mg/dl) 114.1 ± 22.5 (65–269) 108.1 ± 19.4 (78–272) (<0.05)
HbA1c (%) 6.1 ± 0.9 (1.4–12.0) 6.1 ± 0.7 (4.8–11.7) (NS)
IGT, n (%) 883 (83.1%) 777 (74.2%) (NS)
ALT (IU/l) 41.0 ± 27.0 (7–210) 27.5 ± 19.8 (6–228) (<0.001)
AST (IU/l) 28.3 ± 14.1 (9–139) 23.8 ± 11.0 (10–153) (<0.001)
GGT (IU/l) 67.9 ± 66.1 (10–663) 33.8 ± 30.6 (7–424) (<0.001)
FIB-4 index 1.2 ± 0.8 (0.24–13.7) 1.2 ± 0.5 (0.30–3.13) (<0.005)
Fatty liver, n (%) 799 (75.2%) 602 (57.5%) (<0.001)
V-type MS, n (%) 657 (61.8%) 154 (14.7%) (<0.001)
Alcohol consumption, n (%) 784 (73.8%) 250 (23.9%) <0.001
Past history of smoking, n (%) 771 (72.5%) 82 (7.8%) <0.001
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose;
GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; IGT, impaired glucose tolerance; LDL, low density
lipoprotein; MS, metabolic syndrome; NS, not significant; SBP, systolic blood pressure; T-CHO, total cholesterol; TG, triglyceride; UA, uric acid; V-type,
visceral type; WC, waist circumference.
Data are given as means ± standard deviation (SD), and as number (%) for categorical variables. P-value is based on the χ2 test or Student’s t-test.
Significant is at the 5% level.
a: Adjusted for age, BMI, WC, smoking history, hyperlipidemia, hypertension, and, IGT.
https://doi.org/10.1371/journal.pone.0177925.t002
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with MS than in females with MS, there was no significant difference in the prevalence of FL
with ALT elevation between genders with MS in those receiving treatment for IGT. However,
the prevalence of FL with ALT elevation was significantly higher in males with MS than in
females with MS in those without treatment for IGT. The prevalence of those with a past his-
tory of smoking and light alcohol consumption (LAC) was significantly higher in males with
MS than in females with MS. The prevalence of FL with ALT elevation was significantly higher
in males with MS than in females with MS in both those with and without a past history of
smoking or LAC.
Discussion
The aim of the present study was to compare the clinical backgrounds of males and females
with MS, and to explore the differing influence of lifestyle-related factors, and visceral fat on
FL with ALT elevation between genders with MS. Although MS has been known to be strongly
associated with NAFLD in both sexes, the prevalence of MS and NAFLD is different between
genders [8, 9]. Although there are some reports of an association between NAFLD and clinical
backgrounds in individuals with MS [10, 11], the differing influence of lifestyle-related factors
and visceral fat on FL with elevation of liver enzymes between genders with MS is unclear. The
Table 3. Comparison of clinical characteristics in each MS type and each gender.
Males Females P-value (P-valuea)
(1) V-type MS (2) S-type MS (3) V-type MS (4) S-type MS (1) vs (2) (3) vs (4) (1) vs (3) (2) vs (4)
(n = 657) (n = 406) (n = 154) (n = 893)
Age (years) 52.2 ± 10.0 55.3 ± 8.8 52.7 ± 8.9 57.6 ± 8.0 <0.001 <0.001 NS <0.001
BMI (kg/m2) 28.5 ± 3.4 27.7 ± 3.2 27.3 ± 3.7 26.1 ± 3.5 <0.001 <0.001 <0.001 <0.001
WC (cm) 96.9 ± 7.3 96.0 ± 6.7 91.5 ± 7.4 89.7 ± 7.1 <0.05 <0.01 <0.001 <0.001
SBP (mmHg) 129.1 ± 15.0 130.5 ± 15.1 130.4 ± 13.1 131.1 ± 14.4 (NS) (NS) (NS) (NS)
DBP (mmHg) 79.9 ± 10.1 80.1 ± 10.3 79.1 ± 9.1 77.6 ± 9.6 (NS) (NS) (<0.05) (<0.005)
T-CHO (mg/dl) 206.7 ± 36.4 202.0 ± 35.4 212.2 ± 27.7 211.5 ± 34.0 (NS) (NS) (NS) (<0.01)
TG (mg/dl) 180.7 ± 98.9 170.6 ± 116.6 141.7 ± 59.9 119.8 ± 63.4 (NS) (<0.001) (<0.005) (<0.001)
HDL (mg/dl) 48.6 ± 11.0 50.2 ± 10.7 56.3 ± 12.0 60.1 ± 14.0 (NS) (NS) (<0.001) (<0.001)
LDL (mg/dl) 135.3 ± 32.7 130.6 ± 31.1 137.5 ± 25.4 135.2 ± 30.7 (NS) (NS) (NS) (<0.05)
UA (mg/dl) 6.4 ± 1.4 6.3 ± 1.3 5.3 ± 1.1 4.9 ± 1.1 (NS) (<0.001) (<0.001) (<0.001)
FPG (mg/dl) 115.0 ± 24.0 112.7 ± 19.7 113.0 ± 24.5 107.2 ± 18.3 (NS) (<0.005) (NS) (NS)
HbA1c (%) 6.2 ± 0.9 6.1 ± 0.8 6.3 ± 1.0 6.0 ± 0.6 (NS) (<0.05) (NS) (<0.001)
ALT (IU/l) 47.0 ± 28.0 31.2 ± 21.9 38.0 ± 24.2 25.7 ± 18.3 (<0.001) (<0.001) (<0.001) (NS)
AST (IU/l) 30.7 ± 14.4 24.6 ± 12.6 28.9 ± 15.1 22.9 ± 9.9 (0.001) (0.001) (NS) (NS)
GGT (IU/l) 73.3 ± 67.5 59.3 ± 62.9 42.8 ± 33.6 32.3 ± 29.8 (<0.005) (<0.001) (<0.005) (<0.001)
FIB-4 index 1.1 ± 0.5 1.3 ± 1.1 1.1 ± 0.5 1.2 ± 0.5 (NS) (NS) (NS) (NS)
FL with ALT elevation (+/-) 431/226 (65.6%) 97/309 (23.9%) 77/77 (50.0%) 160/733 (17.9%) (<0.001) (<0.001) (<0.01) (NS)
Alcohol consumption (+/-) 469/188 (71.4%) 315/91 (77.6%) 39/115 (25.3%) 211/682 (23.6%) <0.05 NS <0.001 <0.001
Past history of smoking (+/-) 468/189 (71.2%) 303/103 (74.6%) 8/146 (5.2%) 74/819 (8.3%) NS NS <0.001 <0.001
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; FL, fatty liver; FPG, fasting
plasma glucose; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MS,
metabolic syndrome; NS, not significant; SBP, systolic blood pressure; S-type, subcutaneous type; T-CHO, total cholesterol; TG, triglyceride; UA, uric acid;
V-type, visceral type; WC, waist circumference. ALT elevation was defined as ALT level of31 IU/l in this study.
Data represent the means ± standard deviation (SD), and number (%) for categorical variables.
P-value is based on the χ2 test or Student’s t-test. Significant is at the 5% level.
a: Adjusted for age, BMI, WC, smoking history, hyperlipidemia, hypertension, and impaired glucose tolerance.
https://doi.org/10.1371/journal.pone.0177925.t003
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present study showed that V-type MS is a common significant predictor of an increased preva-
lence of FL with ALT elevation in both sexes with MS, however, there were several different
lifestyle-related factors for the prevalence of FL with ALT elevation between genders with MS.
While males with MS and females with MS have been treated in the same manner to date,
we found several differences in physical constitution between genders with MS. Although the
visceral fat area is larger in individuals with MS than in those with non-applicable MS, we
noticed that there may be a difference in the proportion of visceral fat even in the same indi-
viduals with MS, and also, there may be a difference in the distribution of fat accumulation
between genders with MS. The proportion of V-type MS and S-type MS was 38.4% and 61.6%,
respectively in present study; these results suggesting that, although all subjects were diagnosed
with MS, they may not necessary have visceral fat-dominant MS. In addition, there was a con-
siderable discrepancy in the proportion of MS types between genders with MS, in other words,
the proportion of V-type MS (61.8%) was significantly higher than that of S-type MS (38.2%)
in males with MS, and S-type MS (85.3%) was significantly higher than V-type MS (14.7%) in
Table 4. Results of univariate and multivariate analyses: Independent predictors of fatty liver with ALT elevation in males and females with MS.
Males with MS (n = 1063 Females with MS (n = 1047
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
P-value OR 95% CI P-value P-value OR 95% CI P-value
Age (< 50/≧ 50 years) <0.001 2.874 2.110–3.915 <0.001 <0.005 1.007 0.672–1.509 NS
BMI (≧ 25/< 25 kg/m2) <0.001 1.497 0.933–2.403 NS <0.001 2.179 1.425–3.332 <0.001
WC (≧ 95 or 90/< 95 or 90 cm) <0.001 1.831 1.360–2.464 <0.005 <0.001 1.850 1.267–2.702 <0.005
SBP (≧ 130/< 130 mmHg) NS <0.05 0.711 0.506–1.000 NS
DBP (≧ 85/< 85 mmHg) NS <0.05 1.687 1.163–2.449 <0.01
Hypertension (+/-) <0.005 0.970 0.684–1.375 NS
T-CHO (≧ 220/< 220 mg/dl) <0.005 NS
TG (≧ 150/< 150 mg/dl) <0.001 <0.001 2.221 1.558–3.166 <0.001
HDL (< 40 or 50/≧40 or 50 mg/dl) <0.05 <0.001 1.334 0.929–1.915 NS
LDL (≧ 140/< 140 mg/dl) <0.001 NS
Dyslipidemia (+/-) <0.001 1.893 1.339–2.676 <0.005 NS
UA (≧ 7.0/< 7.0 mg/dl) <0.005 1.238 0.907–1.689 NS <0.001 2.911 1.419–5.969 <0.01
FPG (≧ 100/< 100 mg/dl) NS <0.05
HbA1c (≧ 6.2/< 6.2%) <0.05 1.360 1.003–1.845 <0.05 <0.001
IGT (+/-) NS <0.05 1.658 1.112–2.471 <0.05
AST (≧ 31/< 31 IU/l) <0.001 <0.001
GGT (≧ 51/< 51 IU/l) <0.001 <0.001
V-type MS / S-type MS <0.001 5.783 4.288–7.799 <0.001 <0.001 3.828 2.571–5.700 <0.001
Light drinker/ Non-drinker <0.001 0.563 0.407–0.778 <0.005 NS
Past history of smoking (+/-) NS NS
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; FL, fatty
liver; FPG, fasting plasma glucose; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IGT, impaired glucose
tolerance; LDL, low-density lipoprotein; MS: metabolic syndrome; NS, not significant; OR, odds ratio; SBP, systolic blood pressure; S-type, subcutaneous
type. T-CHO, total cholesterol; TG, triglyceride; UA, uric acid; V-type, visceral type; WC, waist circumference. Male subjects who drank from more than zero
but less than 20 g/day of alcohol were defined as light drinkers. Male non-drinkers were subjects who drank 12 drinks or less per year of less than 20 g/
drinking day. Female subjects who drank from more than zero but less than 10 g/day of alcohol were defined as light drinkers. Female non-drinkers were
subjects who drank 12 drinks or less per year of less than 10 g/drinking day. FL with ALT elevation was referred to as FL with ALT level of31 IU/l in the
present study.
Significant is at the 5% level.
https://doi.org/10.1371/journal.pone.0177925.t004
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females with MS. Females are more likely to develop peripheral adiposity with gluteal and sub-
cutaneous fat accumulation, whereas males are more prone to central fat accumulation [12,
13]. Although the mechanism underlying the differences in body fat distribution between gen-
ders are not yet clear, sex hormones may play a major role in determining body fat distribution
[14–17]. For example, body fat distribution changes with shifts in sex hormones during
puberty or menopause [14]. Sex steroids decrease with age and induce a shift in regional body
fat distribution towards a more central fat distribution in both sexes [15, 16]. The difference of
body fat distribution and the proportion of visceral fat between genders or MS types may be
influenced partially by the change and the balance of sex hormones.
Additionally, we noticed that clinical backgrounds might be different between individuals
with V-type MS and S-type MS, even if they were defined as same MS. With regard to physical
constitution, BMI and WC were significantly higher in individuals with V-type MS than in
those with S-type MS in both sexes. With regard to factors associated with lifestyle-related dis-
eases, TG, FPG, HbA1c, and UA were significantly higher in females with V-type MS than in
those with S-type MS. With regard to the influence on the liver, the prevalence of FL with
ALT elevation, ALT, and AST were significantly higher in individuals with V-type MS than in
those with S-type MS in both sexes. V-type MS may be more influenced by various clinical
Table 5. Comparison of the influence of the treatment for lifestyle-related diseases and lifestyle on the prevalence of FL with ALT elevation
between males and females with MS.
Lifestyle-related disease or
lifestyle
Presence of treatment or favorite
item
Males with MS
(n = 1063)
Females with MS
(n = 1047)
P-value(Pa-
value)
Hypertension Treatment (+), n (%) 400 (37.6%) 419 (40.0%) NS
FL with ALT elevation, n (%) 164 (41.0%) 108 (25.8%) (<0.005)
Treatment (-), n (%) 663 (62.4%) 628 (60.0%)
FL with ALT elevation, n (%) 364 (54.9%) 129 (20.5%) (<0.001)
Dyslipidemia Treatment (+), n (%) 226 (21.3%) 387 (37.0%) <0.0001
FL with ALT elevation, n (%) 117 (51.8%) 90 (23.3%) (<0.005)
Treatment (-), n (%) 837 (78.7%) 660 (63.0%)
FL with ALT elevation, n (%) 411 (49.1%) 147 (22.3%) (<0.001)
IGT Treatment (+), n (%) 139 (13.1%) 84 (8.0%) <0.001
FL with ALT elevation, n (%) 65 (6.1%) 28 (2.7%) (NS)
Treatment (-), n (%) 924 (86.9%) 963 (92.0%)
FL with ALT elevation, n (%) 463 (50.1%) 209 (21.7%) (<0.001)
Past history of smoking smoking (+), n (%) 771 (72.5%) 82 (7.8%) <0.001
FL with ALT elevation, n (%) 369 (47.9%) 24 (29.3%) (<0.001)
smoking (-), n (%) 292 (27.5%) 965 (92.2%)
FL with ALT elevation, n (%) 159 (54.5%) 213 (22.1%) (<0.001)
LAC LAC (+), n (%) 784 (73.8%) 250 (23.9%) <0.001
FL with ALT elevation, n (%) 357 (45.5%) 60 (24.0%) (<0.001)
LAC (-), n (%) 279 (26.2%) 797 (76.1%)
FL with ALT elevation, n (%) 171 (61.3%) 177 (22.2%) (<0.001)
ALT, alanine aminotransferase; FL, fatty liver; IGT, impaired glucose tolerance; LAC, light alcohol consumption; MS, metabolic syndrome; NS, not
significant. Male subjects who drank from more than zero but less than 20 g/day of alcohol were defined as positive for LAC. Female subjects who drank
from more than zero but less than 10 g/day of alcohol were defined as positive for LAC.
Data represent the means ± standard deviation (SD), and number (%) for categorical variables.
P-value is based on the χ2 test or Student’s t-test. Significant is at the 5% level.
a: Adjusted for age, BMI, WC, hyperlipidemia, hypertension, IGT, smoking history, and LAC.
https://doi.org/10.1371/journal.pone.0177925.t005
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backgrounds, compared to S-type MS. Visceral fat and subcutaneous fat are both considered
to be central features of MS and, in particular, visceral adipose tissue is thought to be a
source of inflammatory cytokines and to be associated with systemic inflammation in obese
individuals [18, 19]. Tilg et al. proposed that adipocytes and infiltrating macrophages in vis-
ceral adipose tissue produced a large amount of systemically active mediators, including adipo-
cytokines, thought to contribute to low-grade inflammation observed in severe obesity, MS,
and other associated disorders [20]. Visceral fat accumulation was reported to play an impor-
tant role in the development of NAFLD [10, 21, 22]. Elevation of serum ALT is closely associ-
ated with liver fat content and NAFLD, especially in populations with a very high prevalence
of obesity and FL in several epidemiological reports [11]. Moreover, we surmised that there
might be several different clinical characteristics between genders with each MS type. Several
factors associated with lifestyle-related diseases and the proportion of FL with ALT elevation
were significantly higher in males with V-type MS than in females with V-type MS. On the
other hand, although there were some different clinical characteristics between genders with
S-type MS, there was no significantly difference in the prevalence of FL with ALT elevation
between genders with S-type MS. These findings suggest that differences in MS type and gen-
der should be considered for FL with ALT elevation in individuals with MS.
It is known that improvement of lifestyle-related diseases is important for individuals with
MS or NAFLD in both sexes. The present study showed that the prevalence of lifestyle-related
diseases and the influence of lifestyle-related diseases on FL with ALT elevation were different
between genders with MS; however, IGT and dyslipidemia were common important factors
for the presence of FL with ALT elevation in both sexes with MS. Although the cause of
NAFLD is not yet fully understood, in individuals with MS with an increased rate of lipid
ingestion and amount of visceral adipose tissue, free fatty acids produced by neutral fat degra-
dation are increased and flow into the liver via the portal vein [23–25], potentially causing lipo-
toxicity and hepatocyte inflammation. Insulin resistance that has a possibility of leading to fat
accumulation in hepatocytes by lipolysis and hyperinsulinemia may be highly associated with
NASH [26, 27].
Lifestyle, such as smoking and alcohol consumption, is known to influence NAFLD. Exact
pathogenetic roles of the association between smoking and NAFLD and the mechanisms of
smoking-induced fatty changes and fibrosis in the liver are still unclear. Oxidative stress is
known to be a mechanism of injury in NAFLD, and cigarette smoking is thought to be an
inducer of oxidative stress and have pro-inflammatory effects in other organs [28–30]. In the
present study, smoking history was not a significant predictor of FL with ALT elevation in
both sexes with MS. Heavy drinking is known to cause liver injury [31], and light or moderate
drinking has been reported to play a protective role against FL in recent studies [32, 33].
Although the influence of alcohol consumption is known to be markedly different between
genders [34–36], the association between alcohol consumption, including drinking styles and
volume, and NAFLD has remained controversial. Interestingly, although LAC was a significant
predictor of a decreased prevalence of FL with ALT elevation in males with MS, LAC was not a
significant predictor in females with MS. The present findings suggest that males may differ
from females in sensitivity to the hepatic effects of alcohol due to the pharmacokinetics or
metabolism of alcohol [35]. Although the mechanism of the association between LAC and FL
with ALT elevation is unclear, some studies have reported that moderate alcohol intake
enhances insulin sensitivity [37]. LAC may reduce the risk of NASH due to reduced insulin
resistance [32].
Elevation of age has known to be a risk factor for NAFLD in females, but in males. How-
ever, this study showed that age of females with MS was not a significant risk factor for fatty
liver with ALT elevation in multivariate analyses. Generally, the prevalence of NAFLD in
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premenopausal females has known to be lower than in postmenopausal females. These previ-
ous results considered to be related to the state of menses. In this study, the prevalence of alco-
hol consumption in females under 50 years of age who had MS was significantly higher than in
females of 50 years and upward who had MS (data not shown). In addition, the prevalence of
past history of smoking in persons under 50 years of age and persons of 50 years and upward
was 10.9% and 7.1%, in females with MS, respectively (data not shown). Female results in this
study may be more influenced by lifestyle factors, such as drinking and smoking than age and
the state of menses.
The present study showed that the predictors for FL with ALT elevation in males with MS
were partly different from those in females with MS. However, we suggest that it is desirable
for individuals with MS to improve WC and V-type MS, because WC and V-type MS were
common predictors of an increased prevalence of FL with ALT elevation. Additionally, while
the influence of lifestyle-related diseases on FL with ALT elevation was different between gen-
ders with MS, we suggest that it is important for individuals with MS to improve lifestyle-
related diseases such as dyslipidemia and IGT, because the factors associated with dyslipidemia
and IGT were significantly related to FL with ALT elevation. With regard to lifestyle, while
smoking habit was not a significant predictor of an increased prevalence of FL with ALT
elevation, smoking should not be recommended for non-smokers, as cigarette smoking is
known to be strongly associated with lung cancer in various countries [38]. Although LAC was
a significant predictor of a decreased prevalence of FL with ALT elevation in males with MS,
we should not suggest that drinking is recommended for non-drinkers, as the effects of drink-
ing differ among individuals and genders; moreover, lifestyle-related diseases may be affected
by increased eating and the increased calorie intake due to alcohol consumption.
There are several limitations to the present study. First, there was a possible selection bias,
because most of the participants were healthy individuals who hoped to undergo a medical
check-up. Second, detailed information of diets, such as volume and contents including vege-
table and fruits, the duration of eating and drinking, and total caloric intake, were not investi-
gated. Third, the state of menses in females was not investigated, and the levels of estrogen-
related sex hormones in both sexes were not measured. Last, the differences between ethnici-
ties could not be assessed because all subjects were only Japanese.
Conclusions
The present study showed that WC and V-type MS are common significant predictors of an
increased prevalence of FL with ALT elevation in both sexes with MS. However, there were
several different factors associated with lifestyle and lifestyle-related diseases between males
and females with MS that influences the prevalence of FL with ALT elevation. Gender, life-
style-related factors, and MS type in individuals with MS may contribute to the development
of FL with ALT elevation.
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